Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Nehler

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
JACC. Advances|May 13, 2025
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINERShea E Hogan, Mario Enrico Canonico, Robert W King, et al.
Circulation. Cardiovascular Quality and Outcomes|July 4, 2020
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID TrialChandler A Long, Hillary Mulder, F Gerry R Fowkes, et al.
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
Journal of Vascular Surgery|October 1, 2021
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trialNicholas Govsyeyev, Mark R Nehler, Cecilia C Low Wang, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
Journal of the American College of Cardiology|October 29, 2021
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PADConnie N Hess, Manesh R Patel, Rupert M Bauersachs, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
JACC. Advances|May 13, 2025
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINERShea E Hogan, Mario Enrico Canonico, Robert W King, et al.
Circulation. Cardiovascular Quality and Outcomes|July 4, 2020
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID TrialChandler A Long, Hillary Mulder, F Gerry R Fowkes, et al.
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
Journal of Vascular Surgery|October 1, 2021
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trialNicholas Govsyeyev, Mark R Nehler, Cecilia C Low Wang, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
Journal of the American College of Cardiology|October 29, 2021
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PADConnie N Hess, Manesh R Patel, Rupert M Bauersachs, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Pageof 7